fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models

被引:147
作者
Dudhani, Rajesh V. [1 ]
Turnidge, John D. [2 ,3 ,4 ,5 ]
Nation, Roger L. [1 ]
Li, Jian [1 ]
机构
[1] Monash Univ, Facil Antiinfect Drug Dev & Innovat Drug Delivery, Monash Inst Pharmaceut Sci, Melbourne, Vic 3004, Australia
[2] Womens & Childrens Hosp, Adelaide, SA, Australia
[3] Univ Adelaide, Dept Pathol, Adelaide, SA, Australia
[4] Univ Adelaide, Dept Paediat, Adelaide, SA, Australia
[5] Univ Adelaide, Dept Mol & Biomed Sci, Adelaide, SA, Australia
基金
英国医学研究理事会; 美国国家卫生研究院;
关键词
Gram-negative bacteria; emergence of resistance; population analysis profiles; heteroresistance; CRITICALLY-ILL PATIENTS; MULTIDRUG-RESISTANT; PSEUDOMONAS-AERUGINOSA; DISEASES-SOCIETY; BAD BUGS; METHANESULFONATE; PHARMACOKINETICS; HETERORESISTANCE; EMERGENCE; AMERICA;
D O I
10.1093/jac/dkq226
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To elucidate the pharmacokinetic/pharmacodynamic (PK/PD) index that predicts colistin efficacy against Acinetobacter baumannii in neutropenic murine thigh and lung infection models, and to determine the extent of the emergence of resistance in vivo to colistin. PK/PD of colistin was studied in thigh and lung infection models against A. baumannii ATCC 19606 and two multidrug-resistant clinical isolates (two of the three strains were colistin heteroresistant). Dose fractionation studies were conducted over a daily dose range of 1-160 mg/kg colistin sulphate. Bacterial burden in tissues was measured at 24 h. Non-linear least squares regression analyses were employed to determine the PK/PD index (fAUC/MIC, fC(max)/MIC or fT(> MIC)) best correlating with the efficacy of colistin in each model. Real-time population analysis profiles were conducted for tissue samples to monitor the emergence of resistance. The fAUC/MIC was the PK/PD index that correlated best with efficacy in both thigh (R(2) = 0.90) and lung (R(2) = 0.80) infection models. The fAUC/MIC targets required to achieve stasis and 1 log kill against the three strains were 1.89-7.41 and 6.98-13.6 in the thigh infection model, respectively, while the corresponding values were 1.57-6.52 and 8.18-42.1 in the lung infection model. Amplification of colistin-resistant subpopulations was revealed for all strains in both models after 24 h colistin treatment. This study indicates the importance of achieving adequate time-averaged exposure to colistin and defined target fAUC/MIC values for various magnitudes of kill. Amplification of resistant subpopulations indicates the importance of investigating rational combinations with colistin. The results will facilitate efforts to optimize colistin use in humans.
引用
收藏
页码:1984 / 1990
页数:7
相关论文
共 24 条
[1]   Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa [J].
Bergen, Phillip J. ;
Li, Jian ;
Rayner, Craig R. ;
Nation, Roger L. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) :1953-1958
[2]   Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America [J].
Boucher, Helen W. ;
Talbot, George H. ;
Bradley, John S. ;
Edwards, John E., Jr. ;
Gilbert, David ;
Rice, Louis B. ;
Scheld, Michael ;
Spellberg, Brad ;
Bartlett, John .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) :1-12
[3]  
*BRIT SOC ANT CHEM, BSAC METH ANT SUSC T
[4]  
Clinical and Laboratory Standards Institute, 2007, M100S17 CLSI
[5]   Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin [J].
David, Miruna D. ;
Gill, Martin J. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (04) :962-964
[6]   Elucidation of the Pharmacokinetic/Pharmacodynamic Determinant of Colistin Activity against Pseudomonas aeruginosa in Murine Thigh and Lung Infection Models [J].
Dudhani, Rajesh V. ;
Turnidge, John D. ;
Coulthard, Kingsley ;
Milne, Robert W. ;
Rayner, Craig R. ;
Li, Jian ;
Nation, Roger L. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (03) :1117-1124
[7]  
*ESCMID, 2010, CLIN BREAKP TABL INT
[8]   Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy [J].
Hawley, Joshua S. ;
Murray, Clinton K. ;
Jorgensen, James H. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (01) :351-352
[9]   Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration [J].
Li, J ;
Rayner, CR ;
Nation, RL ;
Deans, R ;
Boots, R ;
Widdecombe, N ;
Douglas, A ;
Lipman, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4814-4815
[10]   Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate [J].
Li, J ;
Milne, RW ;
Nation, RL ;
Turnidge, JD ;
Smeaton, TC ;
Coulthard, K .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (05) :837-840